The development of treatment strategies to circumvent this problem may offer attractive opportunities for pharmaceutical intervention in the pathogenesis of obesity, which is the subject of our other study using MTS-leptin—a modified leptin with improved permeation across the BBB. Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.